As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global expansion with Cartistem, its allogeneic human umbilical cord blood-derived ...
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
Zacks.com on MSN1d
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast CancerAstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
The approval was based on results from the TROPION-Breast01 Phase III trial.
In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...
Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...
AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback